KVUE

#412
Kenvue Inc.
17.5210 USD
+1.37%
Sektör: Tüketici - İstikrarlı
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
17.4800
17.5250
Yıllık Aralık
14.0200
19.1750
Günlük Değişim
+1.37%
Aylık Değişim
-1.21%
6 Aylık Değişim
+16.19%
Yıllık Değişim
+16.19%
Önceki Kapanış
17.2850
Açılış
17.4950
Bid
Ask
Düşük
17.4800
High
17.5250
Hacim
675
Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler Temettüler
Çeyreklik Yıllık
  • Market Capitalization 33.5831 B
  • Employee 22 K
  • Founded 2022
  • CEO N/A
  • Website www.kenvue.com
  • Headquarter Delaware, United States
  • FIGI BBG01C79X561
  • Industry Ev ve Kişisel Ürünler
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Total debt
Free cash flow
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
22.62
Price to sales ratio
2.19
Hisse başına temettü
0.82
Temettü getirisi %
4.8

Kenvue Inc

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

Haberler